ESMO Events 2024

Meetings(opens in new tab/window) | ESMO(opens in new tab/window)

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO European Lung Cancer Congress 2024(opens in new tab/window)

The European Lung Cancer Congress (ELCC 2024) is a collaborative effort of important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide. Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• ●

  Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer(opens in new tab/window) C. Rolfo, A. Russo

• ●

  Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer(opens in new tab/window) H.T. Tran †, S. Heeke †, S. Sujit, N. Vokes, J. Zhang, M. Aminu, V.K. Lam, A. Vaporciyan, S.G. Swisher, M.C.B. Godoy, T. Cascone, B. Sepesi, D.L. Gibbons, J. Wu ‡, J.V. Heymach ‡

• ●

  Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial(opens in new tab/window) E. Felip, N. Altorki, C. Zhou, E. Vallières, A. Martínez-Martí, A. Rittmeyer, A. Chella, M. Reck, O. Goloborodko, M. Huang, R. Belleli, V. McNally, M.K. Srivastava, E. Bennett, B.J. Gitlitz, H.A. Wakelee

ESMO Open

• ●

  Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial(opens in new tab/window) S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral †, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell, J. Wolf

• ●

  Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study(opens in new tab/window) D.-W. Kang †, S.-K. Park †, Y.L. Yu, Y. Lee, D.H. Lee, S. Kang

• ●

  Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy(opens in new tab/window) A. Abed, A.B. Beasley, A.L. Reid, N. Law, L. Calapre, M. Millward, J. Lo, E.S. Gray

Immuno-Oncology and Technology

• ●

  CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy(opens in new tab/window)

  J. Dallmann, J. Freitag, C. Jung, K. Khinvasara, L. Merz, D. Peters, M. Schork, J.D. Beck

ESMO Real World Data and Digital Oncology

• ●

  Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations(opens in new tab/window) S.V. Liu, X. Hu, D. Chirovsky, W. Meng, A. Samkari

• ●

  ESMO Guidance for Reporting Oncology real-World evidence (GROW)(opens in new tab/window) L. Castelo-Branco, A. Pellat †, D. Martins-Branco †, A. Valachis †, J.W.G. Derksen †, K.P.M. Suijkerbuijk, U. Dafni, T. Dellaporta, A. Vogel, A. Prelaj, R.H.H. Groenwold, H. Martins, R. Stahel, J. Bliss, J. Kather, N. Ribelles, F. Perrone, P.S. Hall, R. Dienstmann, C.M. Booth, G. Pentheroudakis ‡, S. Delaloge ‡, M. Koopman ‡

ESMO affiliated journals

• ●

  The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives(opens in new tab/window) Miriam Dorta-Suárez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu

• ●

  Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy(opens in new tab/window) Yunfei Chen, Hui Li, Yun Fan

• ●

  Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer(opens in new tab/window) Byoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, Gary L. Buchschacher, Koichi Goto, Tobias R. Overbeck, Herbert H.F. Loong, Cheng E. Chee, Pilar Garrido, Xiaorong Dong, Yun Fan, Shun Lu, Sven Schwemmers, Walter Bordogna, Harald Zeuner, Stuart Osborne, Thomas John

• ●

  Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives(opens in new tab/window) Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.